Tributyrin supplement for blood sugar, inflammation and heart risk in type 2 diabetes
Tests tributyrin added to usual treatment in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07503548, who can take part
Where in Egypt
- Matareya Teaching HospitalCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07503548
- Record updated
- 31 March 2026
- Original description
This study evaluates the effectiveness and safety of tributyrin supplementation in patients with type 2 diabetes mellitus (T2DM) who are at increased risk of cardiovascular disease. Type 2 diabetes is commonly associated with poor blood sugar control, chronic inflammation, oxidative stress, and an increased risk of heart disease.Read full original descriptionShow less
Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes
This study evaluates the effectiveness and safety of tributyrin supplementation in patients with type 2 diabetes mellitus (T2DM) who are at increased risk of cardiovascular disease. Type 2 diabetes is commonly associated with poor blood sugar control, chronic inflammation, oxidative stress, and an increased risk of heart disease.
Tributyrin is a dietary supplement that acts as a precursor to butyrate, a compound known for its anti-inflammatory and metabolic benefits. It may help improve blood sugar levels, reduce inflammation, and lower cardiovascular risk.
In this randomized, double-blind, controlled clinical trial, participants will receive either tributyrin in addition to their standard diabetes treatment or standard therapy alone. The study will assess whether tributyrin improves glycemic control, inflammation, oxidative stress, lipid profile, and overall cardiovascular risk while maintaining safety and tolerability.
Inclusion: • Diagnosed with Type 2 DM for ≥ 1 year; ASCVD 10-year risk ≥ 7.5%; Stable antidiabetic and cardiovascular medication regimen for ≥ 3 months; Able to provide informed consent and comply with study procedures.
Exclusion: • Established cardiovascular disease (history of MI, stroke, or revascularization); Chronic gastrointestinal disorders affecting absorption; Severe hepatic or renal impairment; Use of GLP-1 receptor agonists or SGLT2 inhibitors; Pregnancy or lactation; Known hypersensitivity to tributyrin or butyrate.